Actelion’s Opsumit shows promise in portopulmonary hypertension

Actelion has unveiled new data showing that the first ever randomised, controlled clinical trial investigating Opsumit as potential treatment for portopulmonary hypertension (PoPH) hit its primary target.Original Article